QTREX Quantum Ltd. (NASDAQ: QTEX) announced a securities purchase agreement with an institutional investor for a private placement of 6,666,667 ordinary shares at approximately $10 million in gross proceeds, according to a company statement.

The offering is expected to close on or about June 1, 2026, subject to customary closing conditions. The company plans to use net proceeds for working capital and general corporate purposes after deducting placement agent fees and other offering expenses.

"This financing strengthens our ability to accelerate the commercialization of our AME-based cryogenic interconnect platform, scale our newly acquired AME capabilities, and support research and development across quantum and other mission-critical hardware applications," said Dagi Ben-Noon, Chief Executive Officer of QTREX.

A.G.P./Alliance Global Partners serves as sole placement agent for the offering. The securities are being sold under an exemption from registration requirements under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. The company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the ordinary shares.

QTREX develops additively manufactured electronics technologies for cryogenic interconnect and quantum hardware infrastructure. The company acquired an AME platform and is developing connectivity solutions for dilution cryostats while advancing applications for defense, aerospace, and space environments. The company also maintains a medical technology portfolio including respiratory support and blood monitoring platforms.